RxDataScience Blog

Background

From the outset, the term “Machine Learning” can seem very daunting to those unfamiliar with the technicalities of what this actually means, or so it seemed to me when I was initially assigned to develop a use case for one of these algorithms during my time here at RxDataScience.  From a quick study into the topic, Machine Learning (ML), put simply, is a branch of Artificial Intelligence (AI) that allows a system to automatically learn and improve itself without being explicitly instructed to, by using past and present data to predict certain outcomes [1].  The following video provides a gentle introduction into what ML is all about:

• Kate Spade – depression and anxiety
• Robin Williams – severe depression
• Pete Davidson – Borderline Personality Disorder
• Demi Lovato – Bipolar disorder

Two gone, two battling a lifelong battle, like many Americans. With the stigma and bias surrounding the topic, the mental health community struggles to move forward. The research and treatment is at least a decade behind common chronic conditions, mainly because no one wants to talk about mental health due to the complexity and lack of understanding. 

Introduction to Machine Learning with Random Forest (Pharma/Genetics)

To pick up where we left off last blog post, we discussed the potential of predictive analytics in the genetics of cancer. I aim to achieve this by using the aforementioned Random Forest classification algorithm.

How can AI technology improve the healthcare industry?

Our last blog post explored the implications of a recent study on artificial intelligence (AI) and machine learning business application. While the healthcare industry can expect incredible benefits from the adoption of AI technology, it remains under-adopted and receives below-average attention when compared to other industries.

This post aims to highlight the areas within healthcare where AI has potential. This technology can improve operations, patient experiences, medical procedures, and solve regulatory challenges.

An independent study on machine learning and artificial intelligence (AI) was released by the McKinsey Global Institute (MGI) in June 2017, focusing on the following central question: “Is artificial intelligence the next digital frontier, and if so, are businesses ready for it?”

Using Support Vector Machines

Shruti Kaushik^1,a, Abhinav Choudhury^1,b, Nataraj Dasgupta^2,c, Sayee Natarajan^2,d, Larry A. Pickett^2,e, and Varun Dutt^1,f

Real-World Use Cases for AI & ML in Pharma

For decades, Pharmaceutical data analytics has been a largely manual and tedious task conducted by the commercial research, health outcomes, R&D and Clinical Study groups at Pharma companies both small and large. With the emergence of machine learning, artificial intelligence and other disruptive innovations, Pharma, like other industries has also started its slow but sure transition to a more agile, data-driven model – one where in-house research is supplemented by intelligence gathered by applying algorithms across terabytes of Physician Rx, Patient Claims and other related datasets.